• Free shipping from $200
  • collecting affordable offers from best manufacturers worldwide
  • Special offers every week
Your cart

Category: News and Releases

EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S

WALTHAM, Mass., April 26, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that four abstracts supporting the ongoing development of its proprietary technology cross-linked hyaluronic acid polymer (CMHA-S) have been…

Read More

Press Releases

EyeGate Pharma Treats First Patient in Phase 1b / 2a Trial of EGP-437 in Macular Edema

First Clinical Trial Evaluating EyeGate(R) II Delivery System in Posterior of Eye WALTHAM, Mass., July 14, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the dosing of the…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

-EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- WALTHAM, MA, July 26, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on…

Read More

Press Releases

Eyegate Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants

WALTHAM, Mass., August 5, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the closing of its previously announced underwritten public offering of 1,176,470 shares of common stock, and…

Read More

Press Releases

EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation

– Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development – – Stephen From Elevated from Chief Executive Officer to Executive Chairman – WALTHAM, MA, February 01, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases with…

Read More

Press Releases

EyeGate Pharma To Participate At The 30TH Annual ROTH Conference

WALTHAM, Mass., March 09, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that Stephen From, President and Chief Executive Officer of EyeGate, is scheduled to present at the 30th Annual ROTH Conference being…

Read More

Press Releases

EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

WALTHAM, Mass., September 3, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it will be attending and presenting at the upcoming 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. The conference will…

Read More

Press Releases

EyeGate Pharma Reports Full Year 2019 Financial Results and Provides Business Update

WALTHAM, MA, March 4, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the year ended December 31, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of…

Read More

Press Releases

EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update

WALTHAM, MA, March 25, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced financial results for the year ended December 31, 2020 and provided an update on recent corporate…

Read More

Press Releases